Hints and tips:
...In a research note on Monday, Cowen argued that a number of the large pharmaceutical groups, led by Eli Lilly, Sanofi-Aventis and Pfizer, would be worth more if they divested separable business units, which...
...Bernstein saw Bristol-Myers Squibb, GlaxoSmithKline and Sanofi Aventis among potential buyers of the franchise....
...Our preferred stock picks are Novartis and Sanofi-Aventis.” Sanofi-Aventis climbed 2.5 per cent to €72.65 while Novartis added 1.1 per cent to €71.35....
...Novartis fell 1.4 per cent to SFr69.10 amid talk that it was emerging as the leading contender but others rumoured to be interested included Roche , 1.8 per cent higher at SFr224.0, Sanofi-Aventis , 0ff...
...Sanofi-Aventis, the drugmaker, announced sales growth of 6.5 per cent in the second quarter, a little below expectations, knocking the shares 0.6 per cent to €70....
...Pharmaceuticals were also back in the news, with Sanofi-Aventis falling 2.3 per cent to €62.80 following mixed results from a study of its experimental obesity drug, Acomplia....
International Edition